Background: Trisectionectomy is a treatment option in extensive liver malignancy, including colorectal liver metastases (CRLM). However, the reported experience of this procedure is limited. Therefore, we present our experience with right hepatic trisectionectomy (RHT) for CRLM as an example and discuss the changing role of trisectionectomy in the context of modern treatment alternatives based on a literature review.
| INTRODUC TI ON
Left hepatic trisectionectomy (LHT) was first described in detail by Starzl and colleagues as a left trisegmentectomy in 1982, and then as an extended left hepatectomy by Blumgart et al in 1993. 1, 2 The designation LHT was adopted following the International Hepato-Pancreato-Biliary Association Brisbane 2000 consensus statement on the nomenclature of liver anatomy and resection.
LHT is defined as excision of Couinaud liver segments 2, 3, 4, 5 and 8, with or without segment 1. 3 Despite improvements in surgical techniques and perioperative patient management, only a few papers have reported outcomes of LHT in more than 10 patients. [4] [5] [6] [7] [8] Morbidity and mortality after LHT is higher than for other hepatectomies, and this procedure is reserved for patients with a significant tumor burden and an otherwise dismal prognosis. The high morbidity rate is attributable mainly to the aggressive nature of the disease being treated, but may also be related to the extent of liver volume resected, estimated to be as high as 80
per cent. 2 In 2005, the Leeds group reported long-term outcomes of LHT in 70 consecutive patients. 4 Morbidity rate was high, but the potential for cure supported an aggressive surgical resection policy where other treatment options had been exhausted. In 2016, the same group described changes in surgical practice over time, and analyzed the short-and long-term outcomes of LHT for hepatobiliary malignancy, in order to identify factors associated with morbidity and mortality in the modern era. 9 Right hepatic trisectionectomy (RHT) was first described by Lortat-Jacob, Robert and Henry as right lobectomy in 1952. 10 This operation has had a number of different names, but, until recently, it has been most commonly known as right trisegmentectomy. The designation RHT was adopted following the International Hepato-Pancreato-Biliary Association Brisbane 2000 consensus statement on the nomenclature of liver anatomy and resection. 3, 11 This procedure requires excision of segments 4, 5, 6, 7 and 8 ± 1 and it also remains one of the most challenging major hepatectomies.
Despite improvements in surgical technique and perioperative critical management, perioperative morbidity remains high and only a few hepatobiliary centers worldwide have reported their experience. 12, 13 Modifications of LHT and RHT by in-contiguity and non-anatomical extension and repeat liver resection after LHT or RHT are also rarely reported. 14, 15 The role of these technically demanding and extensive resections in contemporary hepatobiliary practice is established for primary liver cancers and for those tumors with no significant neoadjuvant strategies, but it is also changing as new treatments emerge. This is particularly true for patients with colorectal liver metastases (CRLM), and it is likely that this trend will be followed for other HPB malignancies as more effective preoperative strategies are developed. Emerging data for intrahepatic cholangiocarcinoma, for example, is encouraging. [16] [17] [18] [19] For patients with CRLM, despite the lack of compelling data for most patients, there has been a paradigm shift in the oncological assessment of patients and the use of neoadjuvant and "downstaging" strategies before resection. This has been combined with a sensible development of surgical strategies aimed at parenchymal preservation, along with new developments in liver surgery such as multistage resection as a classical two-stage approach (TSH) or associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). In the classical two-stage approach, portal vein embolization (PVE) or portal vein ligation (PVL) is carried out to stimulate hypertrophy in the planned future liver remnant, along with resection of tumors from the planned future liver remnant (FLR). After an interval of 4-8 weeks, with adequate hypertrophy of the FLR, the definitive resection is carried out. 20 Besides PVL/ PVE, the first step in ALPPS includes at least a 50% transection of liver parenchyma. 21 By this modification, ALPPS seems to be able to accelerate liver growth of the FLR and to shorten the interstage interval. 22, 23 A recent Scandinavian randomized controlled trial has shown the benefits of ALPPS in providing a higher resection rate compared to the classical two-stage procedure, with comparable margins, complications and short-term mortality. 24 However, besides the evolvement of these promising strategies, there remains a place for up-front major resection for many patients. In the light of this trend, we have reviewed in detail a 22-year single-center experience of RHT for CRLM and evaluated factors affecting morbidity and survival in order to provide a critical appraisal for the role of RHT for CRLM in order to add these data to our previous work on LHT.
| ME THODS

| Study design
Patients undergoing RHT between January 1993 and December 2014 were identified from a prospectively maintained database at a single institution. Additional data from the database included radiological investigations and interventions, presence or absence of jaundice, extent of surgical resection, duration of operation, requirement for transfusion of blood or blood products, need for Pringle maneuver or total vascular exclusion, additional surgery (lymphadenectomy, extrahepatic bile duct excision with reconstruction, or vascular reconstruction), histopathological diagnosis, size and distribution of tumors, perioperative morbidity and mortality, and long-term disease-free and disease-specific survival. This work has been reported in line with the PROCESS criteria. 25 All patients undergoing liver resection were offered adjuvant chemotherapy according to guidelines unless they had received adjuvant therapy following their colonic resection within the past 12 months. However, detailed data on adjuvant chemotherapy after colorectal and hepatic surgery were not routinely collected in the database owing to the large number of patients presenting from a wide geographical area of referring hospitals using chemotherapy. In 12 patients, neoadjuvant chemotherapy was used as either a downsizing technique or as a "test of time approach."
| Preoperative evaluation
Preoperative radiological assessment in all patients included thoracic, abdominal and pelvic computed tomography (CT), and magnetic resonance imaging (MRI) of the liver. The investigations were reviewed in a multidisciplinary team meeting to discuss and define the extent of resection. In selected cases, positron emission tomography CT (PET-CT) was used. From 2007, PVE was used when the future liver remnant was estimated to be <20% and was carried out 3 to 4 weeks before scheduled liver resection, but no formal volumetry studies have been done in our center.
| Perioperative care
Techniques of RHT and extensions of RHT have been described previously. 14, 26, 27 Intraoperative ultrasound was carried out in all patients to identify any additional lesions in segments 2 and 3, and their relation to the left portal structures and hepatic veins. All liver transections were carried out using a Cavitron ultrasonic surgical aspirator (CUSA). Pringle's maneuver was applied in selected patients to reduce blood loss and total hepatic vascular exclusion (TVE) (portal triad and hepatic vein or inferior vena cava [IVC] clamping) was used when necessary for tumors located at the hepatocaval confluence. Intraoperative allogeneic red blood cells (ARBC) and fresh frozen plasma were transfused at the discretion of the anesthesiologist.
ARBC were also transfused postoperatively if the hemoglobin level fell to <8.0 g/dL in the absence of cardiac disease and <10.0 g/dL for patients with risk factors for cardiac disease according to our unit policy. No patients received autologous blood transfusion.
| Morbidity and mortality
Details of complications were obtained from the database and, where necessary, from the patient notes and graded according to the validated Clavien-Dindo classification system. 28 Postoperative liver failure was defined according to the International Study Group of Liver Surgery. 29 Postoperative mortality was defined by the occurrence of death within 90 days of surgery or at any time during postoperative hospital stay.
| Histopathological evaluation
Pathological reports were reviewed to determine tumor histological grade, margin status, and histological abnormalities in the non-tumorbearing liver (NTBL). A tumor-free resection margin of less than 1 mm was classified as (R1), and 1 mm or more was classified as (R0). 30 In relation to NTBL, liver steatosis was defined as diffuse accumulation of fat droplets affecting >5% of hepatocytes. 31 Fibrosis was scored according to the Metavir score, and defined as the presence of portal fibrosis with/without septa, numerous septa, or cirrhosis. 32 Sinusoidal injury was graded and defined as the presence of centrilobular involvement beyond one-third of the lobular area. 33 These findings in NTBL were defined as parenchymal liver damage in the present study.
| Follow up
All patients were followed up regularly at the outpatient clinic at 1, 3, 6 and 12 months in the first year, 18 and 24 months in the second year, and yearly thereafter if the patient remained disease-free.
Follow up included clinical examination and assessment of tumor markers (carcinoembryonic antigen [CEA], cancer antigen [CA] .
Surveillance imaging included CT scans of the chest, abdomen, and pelvis at 3, 6, 12, 18 and 24 months, annually to 5 years and again at 7 and 10 years. MRI and PET-CT were carried out if recurrence was suspected in routine follow up. 
| Survival
| Statistical analysis
| RE SULTS
| Patient characteristics
Between January 1993 and December 2014, a total of 3946 liver resections were carried out at this single UK center. Of these, 399 (10%) patients underwent RHT, of whom 188 (47%) patients (hepatocellular carcinoma, n = 35 (18.5%); non CRLM, n = 31 (16.5%); hilar cholangiocarcinoma, n = 36 (19%); intrahepatic cholangiocarcinoma, n = 20 (11%); gallbladder cancer, n = 16 (8.5%); benign liver tumor, n = 15 (8%); other malignant liver tumor, n = 6 (3.2%); other benign bile duct disease, n = 5 (2.7%); RHT as part of auxiliary orthotopic liver transplantation, n = 24 (12.8%) were excluded.
A total of 211 patients were included: 126 (60%) male, 85 (40%) female with a median age of 62 years (range, 25-85). All of the 211 patients included in this analysis underwent RHT for CRLM.
| Tumor characteristics
In the cohort, 49 patients (23%) had solitary tumors and median size of the largest tumor was 50 (range 8-410) mm. Neoadjuvant chemotherapy was given to 12 (5.6%) patients. In 13 (6%) patients, portal vein embolization was done before the actual surgery.
Twenty-five (12%) and 80 (38%) patients underwent concomitant segment (S)1 and/or S2/S3 metastectomy, respectively. Three (1.4%) patients underwent ex vivo resection. Thirty-two (15%) patients required additional organ resection: in 19 (59%) patients, the diaphragm had to be resected, followed by large bowel n = 8 (25%) and others n = 5 (16%). In 72 (34%) of the patients, some form of parenchymal liver damage was noted: 57 (27%), six (3%) and 18 (9%) with steatosis, fibrosis and sinusoidal obstructive syndrome, respectively. Some patients had two or three duplicate types of liver damage. Table 1 . Thirty-eight (18%) patients had more than two postoperative complications. Re-laparotomy was carried out in 19 (9%) patients of the cohort, the main reason being intra-abdominal bleeding n = 9 (47.4%). Four (21%) of the patients who underwent re-laparotomy died in hospital.
| Short-and long-term outcomes, morbidity and mortality
Of the whole cohort, 15 (7.1%) patients died in hospital. One other patient (0.5%) died within 90 days following surgery. Therefore, 16 patients (7.6%) died within 90 days. Among these 16 patients, main causes for mortality were as follows: seven (44%) patients died from multi-organ failure; three (19%) patients died as a result of gastrointestinal bleeding; two (13%) due to acute myocardial infarction; one (6%) as a result of pneumonia or intra-abdominal abscess (n = 1, 6%); massive abdominal bleeding (n = 1, 6%) in hospital; and unknown cause (n = 1, 6%) after discharge. The 211 included patients were further divided into three time periods where 70 patients were included in the first period, 70 patients in the second period and 71 patients in the third period, respectively. With increasing experience at our center we were able to decrease 90-day mortality from 12.8% to 7.1% and 2.8% accordingly. These differences were not significant.
Univariate analysis for morbidity showed that other organ resection (P = .017) and ARBC transfusion (P = .012) were markers for poor outcome. Both variables were also found to be independent predictors for morbidity in multivariate analysis (odds ratio 
| Changes in outcomes over time and redosurgery for recurrence
To evaluate the impact of the learning curve and changes over the study period, patients were divided into three operative experience periods: first (n = 70; 33.2%), second (n = 70; 33.2%), and third (n = 71; 33.6%) period as described in Figure 1 ).
| D ISCUSS I ON
Several centers worldwide have reported their experience with RHT or LHT and extensions of RHT for a variety of indications in HPB malignancies. However, the existing evidence on this topic is scarce and limited to small numbers. Only a few studies for RHT and LHT have reported their experience in larger cohorts. 5, 7, 9, 13, 14, 26, [34] [35] [36] This limited evidence might reflect the changing role of these demanding and extensive resections in daily HPB practice, with decreasing numbers being carried out today. This must be at least in part due to promising results for newly implemented surgical strategies such as TSH and ALPPS, along with oncological advances with better understanding of tumor biology resulting in increasing success with neoadjuvant treatment.
Extended resections have been associated with high morbidity and mortality rates. 37 In 1988, Iwatsuki and Starzl reported their experience showing a mortality rate of 6.3% following right trisectionectomies in their series. 37 In our original report of 275 patients undergoing trisectionectomies including various HPB malignancies, postoperative morbidity was 41%. 26 Thirty-day and 90-day mortality rates were 7% and 8%, respectively. 26 In this up-to-date study, morbidity among all RHT trisectionectomies carried out was 40.3%, and 30-day and 90-day mortality rates were 7.1% and 7.6%, respectively, following this procedure. In a separate analysis assessing morbidity and mortality rates over time, we have been able to show a tendency for reduced morbidity and mortality. These results have been confirmed by other groups. 36 In their series of RHT, Matsumoto et al showed a morbidity rate of 27% and a mortality rate of 0%. 36 These results seem to be comparable with outcomes following modern approaches such as TSH or ALPPS. 24 In extensive liver resections, the size of FLR may have a crucial impact on postoperative morbidity and mortality. In general, 3%-5% of patients may develop liver failure following liver resection. In the present study, the incidence of transient liver failure was 12% (mainly grade A or B according to the International Study Group of Liver Surgery) and reflects the magnitude of surgery. Controversy exists about the amount of liver volume essential to prevent liver failure following these operations. After RHT, FLR is variable but approximately 15%-30% of the total liver volume is preserved. Recent studies have shown that FLR of less than 25%-30% is predictive of hepatic dysfunction. 38 Therefore, the use of PVE before trisectionectomy has been advocated to decrease postoperative morbidity and mortality and make these operations safer. 39 When assessing PVE in the preoperative setting of right trisectionectomies, several studies have shown the importance of embolizing segment 4 to achieve sufficient hypertrophy. 40, 41 Indeed, this has become part of our routine for patients with CRLM after chemotherapy before RHT and, in recent years, we have not experienced any postoperative mortality.
In the present study, multivariate analysis identified additional organ resection at the time of RHT and perioperative ARBC transfusion as independent predictors of postoperative morbidity. In this series, concomitant organ resection was carried out in 32 patients (15.2%) of the cohort.
The diaphragm or large bowel was resected most frequently. The inferior outcome following multi-organ resection most likely reflects a poor and aggressive tumor biology as well as advanced tumor stage.
In other studies, intraoperative blood loss and concomitant blood transfusion were identified as independent risk factors influencing morbidity, mortality and DSS. 9, [42] [43] [44] Our study further identified multiple tumors and R1 resections as independent predictors for recurrence and poor survival following liver resection for CRLM. [45] [46] [47] [48] [49] [50] This corresponds to results of other studies. [51] [52] [53] Sasaki et al clearly identified tumor size and number of CRLM as prognostic markers predicting outcome following resection of CRLM. 54 Furthermore, our study identified TVE as an independent risk factor for poor survival.
This might be due to advanced tumor stage when TVE was applied with invasion to the hepatocaval confluence or IVC. The radicality of surgery required, is associated with an increased potential for postoperative complications, this might be due to the fact that this type of surgery can potentially cause significant hemodynamic instability. [55] [56] [57] Furthermore, in animal studies, TVE has been clearly linked to accelerated growth of hepatic micrometastases. 50 TA B L E 5 Changes in pre-and intraoperative management and postoperative outcomes according to the experience period palliative chemotherapy only. Furthermore, there was no postoperative mortality among patients who underwent repeat resections and none developed liver failure in the further postoperative course.
A limitation of the present study is the incomplete data on chemotherapy. As a result of this limitation, a detailed analysis of the role of chemotherapy in this treatment algorithm was not possible.
Only a relatively small proportion of patients received neoadjuvant therapy for downsizing, but the proportion in whom downsizing strategies failed was not captured in the data set.
| CON CLUS ION
Left hepatic trisectionectomy and RHT are technically demanding liver resections with a high risk for perioperative morbidity and, in the past, also mortality. Our data show these risks are reducing with experience, better patient selection, and the more liberal use of PVE.
LHT and RHT remain relevant for many situations but innovation in surgery and neoadjuvant treatments inevitably mean that the role of these challenging operations is decreasing.
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